Aquestive Therapeutics Inc. (AQST)
$5.34
$-0.01
(-0.19%)
As on 04-Sep-2026 19:31EDT
Market cap
$670 Mln
Revenue (TTM)
$54 Mln
P/E Ratio
--
P/B Ratio
14.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
37.91
-
EV/EBITDA
-1.8
-
Debt to Equity
-0.9
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
125,511,648
8 Years Aggregate
CFO
$-170.16 Mln
EBITDA
$-226.31 Mln
Net Profit
$-376.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
| -17.3 | 40.9 | 32.5 | 35.2 | 47.3 | 3.3 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
| 81.5 | 75.4 | 123.9 | -76.8 | -27.3 | -8.1 | -7.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
5.3 | 670.2 | 54.1 | -78.2 | -114.5 | -- | -- | 14.1 |
| 17.4 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 188.5 | |
| 206.7 | 10,826.1 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 131.0 | |
| 74.8 | 14,630.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 111.6 | 12,065.9 | 830.8 | 54.9 | 3.2 | 8.1 | 248 | 17.3 | |
| 12.0 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 24.5 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 285.6 | 5,693.6 | 290.5 | 197.2 | 82.5 | 19.9 | 29.8 | 5.9 | |
| 68.7 | 6,145.7 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 30.7 | |
| 124.7 | 8,210.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 19.0 |
Shareholding Pattern
View DetailsAbout Aquestive Therapeutics (AQST)
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of... buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Read more
-
CEO, President & Director
Mr. Daniel Barber
-
CEO, President & Director
Mr. Daniel Barber
-
Headquarters
Warren, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aquestive Therapeutics (AQST)
What is the current share price of Aquestive Therapeutics Inc (AQST) Today?
The share price of Aquestive Therapeutics Inc (AQST) is $5.34 (NASDAQ) as of 04-Sep-2026 19:31 EDT. Aquestive Therapeutics Inc (AQST) has given a return of 47.32% in the last 3 years.
What is the current PB & PE ratio of Aquestive Therapeutics Inc (AQST)?
Since, TTM earnings of Aquestive Therapeutics Inc (AQST) is negative, P/E ratio is not available.
The P/B ratio of Aquestive Therapeutics Inc (AQST) is 14.15 times as on 04-Sep-2026, a 84 premium to its peers’ median range of 7.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-9.40 |
-23.41 |
2024 |
-7.36 |
-5.40 |
2023 |
-17.59 |
-1.30 |
2022 |
-0.90 |
-0.41 |
2021 |
-2.23 |
-1.91 |
What is the 52 Week High and Low of Aquestive Therapeutics Inc (AQST)?
The 52-week high and low of Aquestive Therapeutics Inc (AQST) are Rs 7.55 and Rs 2.93 as of 08-Sep-2026.
What is the market cap of Aquestive Therapeutics Inc (AQST)?
Aquestive Therapeutics Inc (AQST) has a market capitalisation of $ 670 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aquestive Therapeutics Inc (AQST)?
Before investing in Aquestive Therapeutics Inc (AQST), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.